Onko-Gene

Critical literature watch in the molecular oncology of solid tumors

FREN

Clinical

First-line versus second-line use of selpercatinib in treatment of RET fusion-positive advanced non-small cell lung cancer: a cost-effectiveness analysis

Summary

This study evaluated the cost-effectiveness of selpercatinib as a first-line or second-line treatment compared to chemotherapy alone for advanced RET fusion-positive non-small cell lung cancer (NSCLC) from the perspective of US payers. A partitioned survival model was employed to compare clinical outcomes and costs. The findings indicated that selpercatinib, whether used first-line or second-line, was not deemed cost-effective at the current willingness-to-pay threshold of $150,000 per quality-adjusted life-year (QALY). To achieve cost-effectiveness, a substantial price reduction for selpercatinib (approximately 70-77%) would be required. The study concludes that further real-world evidence is needed to inform clinical and health policy decisions.

Critical appraisal

Clinical. This cost-effectiveness analysis, based on a partitioned survival model, evaluates the economic impact of selpercatinib for patients with advanced RET fusion-positive NSCLC. The findings indicate that first-line selpercatinib provides an incremental gain of 0.12 QALYs at an additional cost of $117,682, resulting in an incremental cost-effectiveness ratio (ICER) of $953,637.15 per QALY. For second-line use, it offers an incremental gain of 0.13 QALYs at an additional cost of $68,569, with an ICER of $526,970.29 per QALY. These figures are significantly above the US willingness-to-pay threshold of $150,000 per QALY, meaning selpercatinib is not considered cost-effective at its current price. The RET fusion serves as a predictive biomarker for this targeted therapy. For selpercatinib to become cost-effective, a price reduction of 69.94% in the first-line setting or 77.08% in the second-line setting would be required. This study has immediate clinical impact on drug pricing discussions and reimbursement decisions by payers, potentially influencing patient access to this targeted therapy. It highlights the need for further real-world evidence to inform health policy and clinical decision-makers.

The summary and the appraisal were written by a language model from the title and abstract of the original article. A curator decided to publish it. Methodology